Aethlon Medical (AEMD) Cash from Financing Activities (2010 - 2026)
Aethlon Medical (AEMD) posted Cash from Financing Activities of -$196496.0 for Q1 2026, down 106.59% on a QoQ basis from $3.0 million in Q4 2025, and down 108.33% year-over-year from $2.4 million in Q1 2025.
Aethlon Medical (AEMD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Aethlon Medical's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$196496.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 108.33% year-over-year to -$196496.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 15.6% YoY) and the FY2026 annual result came in at $6.5 million, down 15.6% from the prior year.
- Cash from Financing Activities was -$196496.0 for Q1 2026 at Aethlon Medical, down from $3.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $8.3 million in Q3 2022 and bottomed at -$196496.0 in Q1 2026.
- A 5-year average of $1.4 million and a median of $42572.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities surged 97728.44% — and 2026, when it slumped 108.33%.
- Aethlon Medical's Cash from Financing Activities stood at -$1884.0 in 2022, then soared by 9501.75% to $177129.0 in 2023, then tumbled by 103.99% to -$7073.0 in 2024, then soared by 42269.31% to $3.0 million in 2025, then tumbled by 106.59% to -$196496.0 in 2026.
- Business Quant data shows AEMD's Cash from Financing Activities at -$196496.0 in Q1 2026, $3.0 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Aethlon Medical | 7,224.60 | 7,224.60 | - | -196,496.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -196,496.00 |
| Mar 31, 2026 | -196,496.00 |
| Dec 31, 2025 | 2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | -5,357.00 |
| Jun 30, 2025 | -5,357.00 |
| Mar 31, 2025 | 2.36 Mn |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | -7,073.00 |
| Dec 31, 2024 | -7,073.00 |
| Sep 30, 2024 | -3,832.00 |
| Sep 30, 2024 | -3,832.00 |
| Jun 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 42,572.00 |
| Mar 31, 2024 | 42,572.00 |
| Dec 31, 2023 | 177,129.00 |
| Dec 31, 2023 | 177,129.00 |